Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort by Heinimann, Katja et al.
Journal of
Clinical Medicine
Article
Long-Term Increase of Radiographic Damage and
Disability in Patients with RA in Relation to Disease
Duration in the Era of Biologics. Results from the
SCQM Cohort
Katja Heinimann 1, Johannes von Kempis 1, Rafael Sauter 2, Michael Schiff 3,
Tuulikki Sokka-Isler 4, Hendrik Schulze-Koops 5 and Rüdiger Müller 1,5,*
1 Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, 9007 St. Gallen,
Switzerland; katja@heinimann.ch (K.H.); johannes.vonkempis@kssg.ch (J.v.K.)
2 Clinical Trials Unit, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland; rafael.sauter@gmail.com
3 School of Medicine, University of Colorado, Denver, CO 80111, USA; michael.schiff@me.com
4 Faculty of Health Sciences, Jyvaskyla Central Hospital, University of Eastern Finland, 40620 Jyvaskyla,
Finland; tuulikki.sokka-isler@ksshp.fi
5 Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV,
Ludwig-Maximilians-University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany;
Hendrik.Schulze-Koops@med.uni-muenchen.de
* Correspondence: ruediger.mueller@kssg.ch; Tel.: +4-171-494-1138; Fax: +4-171-494-6312
Received: 27 January 2018; Accepted: 8 March 2018; Published: 13 March 2018
Abstract: Objectives: There is little information on the relation between disease duration, disability
and radiographic outcome since the introduction of biologics into the therapy of rheumatoid arthritis
(RA). No long -term cohort studies have been conducted on this subject so far. To analyse radiographic
damage, disability, and disease activity in RA-patients dependent on disease duration in the Swiss
national RA cohort (SCQM). Methods: The primary outcome was the association between the
radiographic destruction, assessed by Ratingen scores, and disease duration. All patients with at least
one clinical visit were analysed with polynomial and multiple negative binomial models. Results:
The disease duration in the 8678 patients with available radiographs analysed ranged between less
than 1 and more than 65 years (median 8.3). Disease duration and radiographic destruction were
significantly associated with an average increase of Ratingen scores by 8.3% per year. Apart from
disease duration, positive rheumatoid factor was the strongest predictor for radiographic destruction.
While DAS28-scores remained stable in patients with a disease duration of more than 5 years (median
DAS28 2.8), HAQ-DI scores increased continuously by 0.018 for each additional year. Conclusion:
In this RA cohort, patients show a continuous increase of articular destruction and physical disability
in parallel with disease duration. Even when nowadays a satisfactory control of disease activity
can be achieved in most patients, RA remains a destructive disease leading to joint destruction and
physical disability in many patients.
Keywords: disease duration; rheumatoid arthritis; DAS28; HAQ-DI; radiographic destruction;
Ratingen score; rheumatoid factor; ACPA
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease with a variable, but mostly
progressive course over many years after its onset. The disease is associated with progressive
joint destruction [1], a decreased quality of life [2,3], systemic manifestations, and comorbidities [4].
The financial and social burden of this destructive disease has been described in many analyses [3,5–7].
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Several prospective studies found the radiographic joint destruction and disability to progress
continuously over time [1,8]. Wolfe et al. [1] analysed 296 recent onset RA patients from 1973 to
1993. They found an average of 1.0 newly eroded joints per year and patient and a yearly increase in
Sharp score by 4.5 points. Scott [8] reviewed the radiographic progression in therapeutic clinical trials
published between 1995 and 2002. He described an average radiographic progression (Sharp or Larsen
scores) of 2% of maximal possible damage per year, despite treatment with conventional synthetic
DMARDs in the majority of treatment arms.
Treatment strategies have drastically improved over the last decades. Methotrexate [9] and tight
control strategies [10,11] became standard of care in the 1980s and 1990s. With the introduction of
biologic agents [12] the spectrum of therapeutic options broadened and a new era began [13].
In clinical trials, a great improvement of disease activity, radiographic course, and functional
ability was found under biologic treatment as compared to methotrexate monotherapy [12,14–16].
This positive effect on functional disability was confirmed in various cohort studies [17,18] outside
the setting of clinical trials. However, other cohort studies could not reproduce this effect [6,19].
The general observation among rheumatologists, that radiographic progression has become milder
over the last decades [20,21] was found to be attributable to the treatment with DMARDs as well [22].
To our knowledge, there are no observations of radiographic damage in RA in relation to the disease
duration in the era of biologic treatment.
The aim of this study was to investigate the radiographic destruction, disability, and disease
activity depending on disease duration in this new era of available biologic treatment. This was
analysed cross-sectionally within the SCQM (Swiss Clinical Quality Management) cohort using patient
data collected over the last 20 years.
2. Methods
2.1. Study Population and Design
This cohort study analyses data from the SCQM, a registry run by office or hospital-based
rheumatologists since 1996. Inclusion criteria for the analysis were a diagnosis of RA by a
rheumatologist. Clinicians participating in the SCQM provide clinical patient data and radiographs
of hand and feet on a regular basis. A central reader from the SCQM assesses these radiographs for
destruction using Ratingen erosion scores (range 0–190) [23]. A more detailed description of the SCQM
registry is described elsewhere [24].
2.2. Exposure of Interest
Patient data from the last visit available in the database were analysed cross-sectionally dependent
on their individual disease duration. The disease duration was defined as the time between the first
diagnosis and the last follow up visit documented in the SCQM database. Our analysis takes into
account data entered into the SCQM database between 1998 and November 2015.
2.3. Inclusion/Exclusion Criteria
RA patients with one or more clinical visits available in the database were included in the analysis.
We excluded patients with missing information on disease duration. All outcomes were exclusively
analysed based on available data. Missing observations were considered to be missing at random and,
therefore, no assumptions for these missing data were made.
2.4. Outcome Parameters
The association between the radiographic destruction, assessed by Ratingen erosion scores at
the last visit, and the disease duration, was the primary outcome of interest. Disease activity and
disability in dependence of disease duration, served as secondary outcomes and were evaluated using
DAS28 [25] and HAQ-DI scores [26], respectively.
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We hypothesised, that disease duration, age, gender, rheumatoid factor (RF), ACPA (anti citrullinated
peptide antibodies), and therapeutic status regarding the use of anti-TNF drugs and methotrexate (MTX),
explain a significant amount of the variability of the investigated outcomes.
2.5. Statistical Analysis
The possible non-linear association between our outcomes of interest (Ratingen erosion score,
HAQ-DI, DAS28) and the disease duration was investigated with an exploratory, non-parametric
local polynomial regression (loess function in R-package stats) using a smoothing parameter of 0.5,
which corresponds to bandwidth of six months of disease duration. The results are illustrated as
smoothed time trends with a 95% confidence interval.
Due to possible confounding factors (age, gender, RF, ACPA, MTX exposure and anti-TNF drug
exposure), the hypothesised dependency between the response variables (Ratingen erosion score,
HAQ-DI and DAS28) and the disease duration was also investigated with parametric regression
models. As the Ratingen score is a count variable which is characterized by strong over dispersion
(mean 24.3, variance 923.8), a multiple negative binomial regression model was applied to model this
outcome. The expected dependencies between HAQ-DI or DAS28 and disease duration were analysed
with multiple linear regression models. The latter outcome was examined with a regression model
that reflects the initial decrease and following increase in the outcome (DAS28 and HAQ) by the use of
two time-dependent regression parameters: one for the disease duration below and the second for the
disease duration above five years.
Additionally, we investigated correlations between (a) Ratingen scores and HAQ-DI, as well as
(b) DAS28 scores and HAQ-DI. Since these variables did not follow a normal distribution, we used
Kendall’s Rank correlation to assess any form of dependency.
All analyses were performed with the R statistics package (R Foundation, Vienna, Austria,
version 3.2.3, R Core Team 2013). We did the negative binomial regression analysis with the procedures
implemented in the MASS library (Venables and Ripley, New York City, NY, USA, version 7.3.45, 2002).
3. Results
3.1. Patients
The analysis was based on 52,753 records of 8678 RA patients available in the SCQM cohort
(status November 2015). Of these we excluded 823 patients due to missing information on disease
duration. Selecting patients with information available for each investigated outcome, the analysis
comprised 6361 patients for Ratingen scores, 6365 patients for DAS28 scores and 5795 patients for
HAQ-DI scores.
3.2. Distribution of Disease Duration
The disease duration ranged between 4 months and 68.8 years (mean 11 years). With increasing
disease duration, we found a logarithmic decline in patient numbers in our cohort. Based on a
regression model with a constant linear decline on the logarithmic scale, the patient population
is estimated to decline by 9.24% per year (Figure 1, R2 = 0.99). There were 462 patients with a
disease duration of more than 30 years. Please refer to Table 1 for a more detailed depiction of the
patient distribution.
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Figure 1. Patient distribution according to disease duration illustrated as individual data (black line) 
and as a histogram representing the subgroups described in Table 1. 
Table 1. Patient characteristics. 
Disease 
Duratio
n (Years) 
Numbe
r (n) 
Age 
(Years
, 
Mean) 
Femal
e * (%) 
BMI * 
(kg/m2
, 
Mean) 
Pos. 
Fam. 
Histor
y * (%) 
RF 
Pos
. * 
(%) 
ACP
A 
Pos. * 
(%) 
Rheumatoi
d Nodules * 
(%) 
Extra-art
. 
Manifes
t * (%) 
MTX 
Pre-expose
d * (%) 
TNF 
Pre-expose
d * (%) 
all 7850 59.9 74.4 26.0 20.6 70.8 62.2 22.7 72.9 81.9 57.7 
<5 2535 57.0 69.2 26.2 15.0 60.8 54.4 7.1 52.3 83.1 42.4 
≥5–10 1990 58.8 74.2 26.4 21.5 69.6 63.9 15.6 61.8 84.1 61.8 
≥10–15 1250 60.8 76.7 26.2 22.1 75.6 66.5 26.3 81.1 83.5 65.2 
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≥25–30 325 65.3 81.8 24.8 24.3 85.5 74.7 51.5 86.3 76.3 67.8 
≥30–40 333 66.5 82.9 25.2 26.7 79.6 70.2 50.8 91.0 77.0 64.4 
≥40 129 71.5 86.0 24.9 31.0 84.3 69.4 56.7 66.7 66.7 62.7 
* analysed on patients with available data; ACPA: anti citrullinated peptide antibodies; RF: 
rheumatoid factor; MTX: methotrexate; TNF: tumour necrosis factor; BMI: body mass index; n: 
number; Pos: positive; Fam.: family. 
3.3. Demographical Data 
The mean age of the patients analysed was 59.9 years. The age increased from an average of 57.0 
years in patients with a disease duration of less than 5 years, to 71.5 years in patients with a disease 
duration of over 40 years. 
The majority of patients analysed was female (74.4%). A positive rheumatoid factor was present 
in 70.8% of patients, ACPA in 62.2% of patients (both analysed on patients with available data). Both 
antibodies were less frequent in patients with recent onset RA and increased with longer disease 
duration. 
Past or current exposure to MTX was reported for 81.9 % of the patients. There was a slightly 
lower rate of MTX exposure in patients with a disease duration of more than 20 years. The rate of 
patients pre-exposed to anti-TNF drugs increased with time from 42.4% in patients with a disease 
duration of less than 5 years, to between 60 and 70% of patients with a longer disease duration. 
27.5% of all patients had a history of other biologic treatment than TNF antagonists (data not 
shown). 
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* analysed on patients with available data; ACPA: anti citrullinated peptide antibodies; RF: rheumatoid factor; MTX:
methotrexate; TNF: tumour necrosis factor; BMI: body mass index; n: number; Pos: positive; Fam.: family.
3.3. Demographical Data
The mean age of the patients analysed was 59.9 years. The age increased from an average of
57.0 years in patients with a disease duration of less than 5 years, to 71.5 years in patients with a
disease duration of over 40 years.
ajority of patients a alysed was female (74.4%). A positive rheumat id factor was present
in 70.8% of patients, ACPA in 62.2% of patients (both nalysed on patie ts with available data).
Both a tibodi s wer less frequent in patients with recent onset RA and increased with longer
disease duration.
Past or current exposure to MTX was reported for 81.9 % of the patients. There was a slightly
lower rate of MTX expos re in patients with a dis ase duration of more than 20 years. The rate of
patients pre-exposed to anti-TNF drugs increased with time from 42.4% in patients with a disease
duration of less than 5 years, to between 60 and 70% of patients with a longer disease duration. 27.5% of
all patients had a history of other biologic treatment than TNF a tagonists (data not shown).
3.4. Primary Outcome
The local polynomial regression model for Ratingen scores revealed a continuous rise of
radiographic destruction with increasing disease duration (Figure 2). This increase of the Ratingen
score was less pronounced during the first few years of the disease. The negative binomial regression
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model demonstrates an increase of the radiographic destruction by 8.6% (Figure 2A) for each additional
year of disease. Apart from time, a positive rheumatoid factor and pre-exposure to anti-TNF drugs
were the strongest predictors for joint damage. ACPA positivity and MTX pre-exposure, on the other
hand, were associated with lower Ratingen scores (Figure 3).
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Figure 2. Smoothed time trends for radiographic damage, disease activity, and patient centred outcome:
(A) Ratingen scores, (B) DAS28 scores, and (C) Health assessment questionnaire-disability index
(HAQ-DI) scores in dependence of disease duration as modelled by local polynomial regression using
a smoothing parameter of 0.5. Results are shown with 95% confidence intervals (CI, grey shade).
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during the first 5 years since diagnosis (p = 0.004) and a time-dependent increase when disease 
duration was greater than 5 years (p = 0.0001) with an increase of the HAQ-DI by 0.175 points for 
each year. The parameter estimates for the possible confounders are shown in Figure 3, third 
column. Positive rheumatoid factors increased the HAQ-DI by 0.11, while male gender and ACPA 
positivity resulted in lower HAQ-DI scores (by 0.20 and 0.24 respectively). MTX pre-exposure was 
associated with a HAQ-DI score of 0.12 points less, while the HAQ-DI scores of patients under past 
or current treatment with TNF-antagonists were higher by 0.13 points. All variables were significant 
on a level of <0.0001. 
With regard to disease activity, a decrease of DAS28 by 0.22 points was apparent within the first 
five years of disease (Figure 3, second column). A positive rheumatoid factor was associated with a 
DAS28 score that was 0.33 points higher, while positive ACPA is associated with DAS28-scores that 
are 0.45 points lower. These variables were significant on a level of <0.0001. Age had only a minimal 
effect on disease activity, while TNF antagonist-exposure, and time since diagnosis more than 5 
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As both Ratingen scores (Figure 2A) and HAQ-DI scores (Figure 2C) increased with disease 
duration, we analysed whether Ratingen scores correlated with HAQ-DI scores in this cohort. This 
Figure 3. (Column A) Results for the negative binomial regression model with the Ratingen score
as outcome. The estimate for each of the parameters indicates the percentage change in Ratingen
score associated with a change of said parameter. While most variables included in the model are
binary, for the continuous variables, such as time since diagnosis and age, the estimates refer to an
increase of the parameter by 1 unit. Values greater than 1 indicate a positive association, smaller than
1 indicate a negati e ass ciati . esults for the linear regression models for (Column B) the DAS28
score and (Column C) the HAQ-DI. The esti t f f t e parameters indicates how muc the
score changes in absolute, if only this parameter changes. While most variables included in the model
are binary, for the continuous variables, such as time since diagnosis and age, the estimates refer o an
increase f the parameter by 1 unit. Values greater than 0 indicate a positive associa ion, maller than
0 indicate a negative ssociation.
3.5. Secondary Outcomes
In patients with disease duration of 5 years or less, the DAS28 score, as well as HAQ-DI scores,
decreased with time (Figure 2B,C). While the majority of patients with a disease duration of more than
5 years remained in low disease activity (Figure 2B), there was a steady increase of HAQ-DI for each
additional year of disease duration (Figure 2C).
The multiple linear regression model confirmed a time-dependent decrease of the HAQ-DI during
the first 5 years since diagnosis (p = 0.004) and a time-dependent increase when disease duration
was greater than 5 years (p = 0.0001) with an increase of the HAQ-DI by 0.175 points for each year.
The parameter estimates for the possible confounders are shown in Figure 3, third column. Positive
rheumatoid factors increased the HAQ-DI by 0.11, while male gender and ACPA positivity resulted
in lower HAQ-DI scores (by 0.20 and 0.24 respectively). MTX pre-exposure was associated with a
HAQ-DI score of 0.12 points less, while the HAQ-DI scores of patie t under p st or cu rent treatment
with TNF-antagonists were higher by 0.13 points. All variables were significant on a level of <0.0001.
With regard to disease activity, a decrease of .22 points was a parent within the first
five years of disease (Figure 3, second colu ). i i r eu atoid factor was associated with a
DAS28 score that was 0.33 points higher, hile siti e is associated with DAS28-scores that
are 0.45 points lower. These variables were significant on a level of <0.0001. Age had only a minimal
effect on disease activity, while TNF antagonist-exposure, and time since diagnosis more than 5 years,
had no significant effect at all.
As both Ratingen scores (Figure 2A) and HAQ-DI scores (Figure 2C) increased with disease
duration, we analysed whether Ratingen scores correlated with HAQ-DI scores in this cohort.
This calculation included 5795 patients for the correlation between HAQ-DI and DAS28 scores,
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and 3966 patients for the correlation between HAQ-DI and Ratingen scores. The rank correlation
according to Kendall showed an overall correlation between HAQ-DI and DAS28 of 0.31.
This correlation was the strongest for patients with disease duration of less than 5 years (0.37, Figure 4A)
and decreased with time (0.30 for disease duration 5–15 years, Figure 4B, and 0.23 for disease duration
of >15 years, Figure 4C). No relevant correlation between HAQ-DI and Ratingen scores could be found
(Figure 4D–F).
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Figure 4. Correlation of HAQ-DI with radiographic destruction and disease activity stratified according
to disease duration: The dependency of the HAQ-DI score from (A–C) Ratingen scores and (D–F)
DAS28 scores for patients with a disease duration of <5 years (A,D) 5-15 years (B,E), and >15 years
(C,F) are modelled by local polynomial regression fittings using a smoothness parameter of 0.1. Results
are shown with 95%-CI (grey shade).
4. Discussion
This cross-sectional cohort study analyses disease activity, radiographic joint destruction and
disability in p tients with RA depending on disease dur tion. Our results show that rheumatoid
arthritis today is still a d structiv isease with a high impact on functionality n daily life. This is of
great importance, since these are direct predictors for work disability and mortality in RA [6,27].
4.1. The Extent of Radiographic Damage has Decreased in Comparison to Earlier Analyses
Our data show that with every year of disease duratio the R tingen score increased by 8.6%.
In other words, the Ratingen score doubled within 8.25 years. In comparison, Wolfe et al. [1] found in
1998 an average of 1.0 newly eroded joints per year and patient. They described a 4.5 unit increase in
Sharp score per year. Based on an estimated baseline Sharp score of four in this cohort, this results
in almost a doubling of Sharp scores within the first year. In parallel, Scott et al [8] have reported in
2004 that patients reached 11% of maximal damage by 5 years and over 40% by 20 years. In our cohort,
11% of maximal damage (=Ratingen score of 20.9) was reached after 10 to 15 years of disease duration
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and 40% of maximal damage (=Ratingen score of 76), on a group level, only after more than 40 years of
disease duration (data not shown). In conclusion, the rate of radiographic destruction in RA patients in
our analysis was lower than compared to these historical cohorts. We think that this can be explained
by the improved treatment options available today. In our cohort, 57.7% of the patients were exposed
to TNF antagonists. However, patients with a longer disease duration were already suffering from RA
prior to the introduction of biologic agents. Whether earlier treatment with biologic DMARDs in these
patients would have resulted in a milder disease course with less radiographic destruction and better
functional ability, remains speculative.
4.2. Radiographic Destruction and Use of TNF Antagonists
A disconnect between radiographic progression and disease activity under treatment with biologic
agents has been discussed [28,29]. In the multiple negative binomial regression model (Figure 3A),
we found pre-exposure to TNF antagonists to be associated with greater radiographic destruction.
What at first sight seems like a negative effect of anti-TNF treatment on joint destruction, in our opinion
reflects the characteristics of the patient population receiving biologic DMARDs: Its usually insufficient
control of clinical activity or radiographic progress that leads rheumatologists to the escalation of
treatment with a biologic, in our cohort usually a TNF antagonist, results in a selection of patients
suffering from a more aggressive form of RA. The positive effect of a combination therapy with biologic
DMARDs compared to Methotrexate alone has been demonstrated in many studies [12,14–16] and
was not the subject of this investigation.
4.3. ACPA Positivity Associated with Milder Disease Course
In our analysis, ACPA positivity was a predictor for improved clinical outcomes: It was associated
with less radiographic destruction, lower disease activity and less functional impairment. This stands
in contrast to some studies, that found a positive ACPA profile to be associated with more severe
radiographic damage and a higher disease activity [30,31]. More recent studies confirm our findings,
that the presence of ACPA—in contrast to RF—is at least associated with lower disease activity [32].
4.4. Disconnect between Disability and Radiographic Destruction
In patients who have been suffering from RA for more than five years, data from our cohort
show a continuous increase in HAQ-DI, as well as Ratingen scores over time. However, the implied
presumption that the articular destruction, measured by the Ratingen score, might be responsible for
the impairment in function cannot be confirmed by our data. We found no relevant correlation between
Ratingen scores and HAQ-DI scores. This is in line with the findings of Sokka et al. [33], that there is
only a weak correlation between radiographic destruction and HAQ-DI score. These authors showed
that the HAQ-DI score is primarily explained by the patient’s global assessment of pain. This finding
was reaffirmed by Moleenar et al. [34] in an analysis of 186 RA patients in remission, that found disease
activity and patient’s global assessment of pain to be strongly associated with functional disability
as analysed by HAQ-DI. The hypothesis that radiographic destruction is associated with a loss of
functional ability at a later time of the disease, as suggested by Bombardier et al. [35], cannot be
certificated in this cross-sectional analysis. It has been discussed that joint destruction of large joints
correlates with HAQ-DI scores [36]. This finding cannot be assessed in our analysis as no information
on the radiographic damage of large joints is collected in the SCQM cohort and the Ratingen score
analyses erosions of hands and feet only. In our cohort, the HAQ-DI scores correlated with the
DAS28 scores.
4.5. Extra-Articular Manifestations Increase in Parallel to Disease Duration
The number of patients suffering from extra-articular RA manifestations in our cohort also
increased over time (Table 1), whereas the entity of the extra-articular manifestation is not differentiated
in the SCQM database. While in recent onset patients (disease duration less than 5 years) just over half
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of the patient population is affected, there was a continuous increase over time, amounting to over 90%
after 30 to 40 years of disease duration. These numbers are much higher than the prevalence of 10 to
20% reported in other studies [37,38]. Since therapeutic strategies for extra-articular RA manifestations
have not been well established, it is important to keep out an eye for the long-term development of
extra-articular manifestations, even if good control of joint inflammation has been achieved.
4.6. Strengths and Limitations
This study fills an important gap, as there have been no reports on long-term outcomes in
patients with RA in relation to disease duration since the early 2000s, when biologics had just been
introduced. With a patient population of almost 8000 patients, of which more than half have been
exposed to TNF-antagonists, this patient cohort reflects the increasing use of biologic treatment in RA
patients today.
However, RA registries themselves in our opinion are prone to selection bias by over-representing
patients with a more severe disease course in the long-term follow-ups: RA patients with a milder
disease course, as well as patients who were falsely diagnosed with RA, are more likely to return into
the treatment of family practitioners and, thus, to be lost to follow up.
5. Conclusions
Despite available biologic treatment and achievement of satisfactory control of disease activity
in the majority of patients in our study, RA remains a destructive disease with a high impact on
functionality over the years. In order to further investigate the long-term outcomes of RA in relation to
disease duration and specific treatment strategies, longitudinal studies are needed.
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